Stryker Corporation $SYK Shares Bought by Azzad Asset Management Inc. ADV

Azzad Asset Management Inc. ADV raised its stake in Stryker Corporation (NYSE:SYK) by 1,006.4% in the 1st quarter, Holdings Channel.com reports. The firm owned 6,406 shares of the medical technology company’s stock after acquiring an additional 5,827 shares during the period. Azzad Asset Management Inc. ADV’s holdings in Stryker were worth $2,105,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of SYK. Godfrey Financial Associates Inc. acquired a new position in Stryker in the fourth quarter valued at approximately $26,000. Sankala Group LLC acquired a new stake in shares of Stryker during the 4th quarter worth approximately $26,000. United Financial Planning Group LLC acquired a new stake in shares of Stryker during the 3rd quarter worth approximately $27,000. Atlas Capital Advisors Inc. bought a new stake in shares of Stryker in the 4th quarter worth approximately $27,000. Finally, DJE Kapital AG acquired a new position in Stryker during the 4th quarter valued at approximately $28,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Activity

In related news, VP M Kathryn Fink sold 5,220 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the completion of the sale, the vice president directly owned 13,137 shares of the company’s stock, valued at $3,728,937.45. This represents a 28.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ronda E. Stryker sold 310,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the sale, the director owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 323,264 shares of company stock worth $100,659,489. Corporate insiders own 4.60% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Argus set a $370.00 price objective on Stryker in a research note on Thursday. Needham & Company LLC cut their target price on Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Sanford C. Bernstein set a $410.00 price target on shares of Stryker in a report on Friday, May 1st. Truist Financial restated a “hold” rating and set a $330.00 price target (down from $380.00) on shares of Stryker in a research report on Monday, May 4th. Finally, Robert W. Baird set a $385.00 price objective on shares of Stryker in a report on Friday, May 1st. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $392.87.

Stryker Stock Up 0.8%

Shares of SYK stock opened at $329.86 on Friday. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $404.87. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11. The business’s fifty day moving average is $310.12 and its 200-day moving average is $337.97. The stock has a market cap of $126.46 billion, a PE ratio of 38.18, a price-to-earnings-growth ratio of 2.10 and a beta of 0.77.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). The firm had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the company earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities analysts expect that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, June 30th. Stryker’s dividend payout ratio is presently 40.74%.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.